IVI in the Media
DCVMN and IVI announce international cooperation over five years to strengthen and facilitate collaborations among developing c
DCVMN and IVI announce international cooperation over five years to strengthen and facilitate collaborations among developing countries vaccine manufacturers
March 14, 2013, Shanghai, China — The Developing Countries Vaccine Manufacturers Network (DCVMN) and the International Vaccine Institute (IVI) have announced today their intentions to strengthen and facilitate collaborations among developing countries vaccine manufacturers, to achieve the common goal of protecting people against known and emerging infectious diseases by enhancing the quality and increasing the availability of vaccines in developing countries.
DCVMN and IVI have been working together for many years and wish to strengthen collaboration by sourcing the development, coordination and delivery of training related to vaccine research and development, manufacturing technology, and clinical and regulatory activities.
The two organizations share the vision of rendering developing countries free of suffering from infectious diseases, and aim to work together to foster the discovery, development and delivery of safe, effective and affordable vaccines for the world’s developing nations.
The global population of over 7 billion is growing at the fastest rate in developing countries, where vaccines are most needed. DCVMN, with partners such as IVI, wishes to take up this challenge of providing vaccines to all. Asia is the most populous continent, with 4.2 billion inhabitants accounting for over 60% of the world’s population. The two most-populated countries, China and India, together constitute about 37% of the world's population. Africa is the second most-populated continent, with around 1 billion people, or 15% of the world's population. Twenty-seven members of the Network are located in the Asia Pacific region and dedicated to the well-being of children.
“In engaging with IVI we intend to create an enabling environment for people to live long and healthy lives, free of vaccine preventable infectious diseases, and support the industry to provide continuing education to professionals for sustainable manufacturing excellence” said Dr. Mahendra Suhardono, DCVMN President. “With 38 members of our Network we represent the largest association of vaccine manufacturers globally, and together we can reach out to every child,” he added.
DCVMN plans to initiate a Continuing Educational Program for professionals engaged in vaccine manufacturing as one component of a comprehensive initiative that aims to provide training on quality management and GMP compliance.
“The partnership with DCVMN is a great step forward in realizing IVI’s vision of developing countries free of suffering from infectious diseases,” said Dr. Christian Loucq, Director-General of IVI. “IVI has a history of working with vaccine manufacturers, particularly in Asia, in manufacturing technology and clinical and regulatory activities so we look forward to a close collaboration with DCVMN in order to help us make a greater impact on improving the health of the poorest people through vaccines.”
The Developing Countries Vaccine Manufacturers Network (“DCVMN”), envisions to protect people against known and emerging infectious diseases globally by increasing the availability and enhancing the quality of vaccines produced in developing countries, by working to strengthen vaccine manufacturers through the provision of technical assistance, training and encouraging technology transfer initiatives, innovative research, facilitating information sharing, and educating the public about the availability of safe and effective vaccines from developing countries manufacturers. The Developing Countries Vaccine Manufacturers Network (DCVMN) is a unique model of public and private international alliance assembling governmental and private vaccine manufacturers towards a common goal of supplying high quality vaccines at affordable prices. Its purpose is to protect people against known and emerging infectious diseases globally by increasing the availability and improving the quality of vaccines produced by emerging country manufacturers. For more information about DCVMN, please visit www.dcvmn.org.
The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 30 countries of Asia, Africa and Latin America on vaccines against diarrheal infections, bacterial meningitis and pneumonia, as well as Japanese encephalitis and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit www.ivi.int.